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Working closely and cooperatively with regulatory author-
ities during drug development is vital to successful drug
development programs. In the United States, the drug
development team includes not only members of the key
disciplines of drug discovery, clinical research, regulatory
affairs, marketing, chemistry, toxicology, and legal aspects,
but also the Food and Drug Administration (FDA). New
regulations encourage meetings at the pre–investigational
new drug (pre-IND), end-of-phase-2, and pre–new drug
application (pre-NDA) submission phases. Appropriate
informal discussions via fax and telephone are also encour-
aged. By proactively interacting with the FDA, the phar-
maceutical industry increases the probability of a successful
drug development program.
n order for a drug to reach the market, three
general elements must be satisfied. The first is for the
product to have a solid scientific rationale based on the
concept of “good science.”If possible,the mechanism of
action should be understood and potential adverse
events anticipated.These concepts can be approached
theoretically as well as in nonclinical pharmacological
studies.While efficacy and safety in humans cannot be
assured by studies in animals,some comfort level can be
achieved by the use of animal models of toxicology.The
second element is for the program to be run with solid
medical principles, or “good medicine.”The main prin-
ciple is to do no harm. No clinical program should
knowingly put any clinical trial subject at risk of harm.
Proper clinical trial designs should be based on accept-
able methods with a profound understanding of the dis-
ease under study. When adverse events appear, a con-
scientious evaluation of their significance to the
individual patient as well as to the population at large,
must be performed. The third element in drug devel-
opment is to assure compliance with regulatory require-
ments, or “good regulations.” Fulfillment of regulatory
requirements is in addition to fulfillment of the require-
ments of “good science”and “good medicine.”The reg-
ulations ensure that regulatory bodies such as the Food
and Drug Administration (FDA) can properly review
and evaluate a drug development program in a stan-
dardized manner.
The team
The drug development team includes a diverse group
of individuals with different philosophies and
approaches to the development process.All team mem-
bers must work closely together to ensure that a drug is
both safe and efficacious.
Discovery/development
The discovery and development groups are comprised of
the basic scientists and chemists who created the new
molecule. This group synthesizes drug substances for
“drug-screening,”pharmacology,and toxicology studies,
and also prepares clinical supplies.
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Basic researchNonclinical pharmacology and toxicology
This group studies the drug product in animal models of
efficacy and safety in order to identify potential efficacy
and safety issues in humans. It is critical for the clinical
and development groups to work closely with the toxi-
cologists in the design of animal studies to ensure their
relevance to the clinical environment.
Clinical research
Clinical research has the ultimate responsibility for
testing drug products in humans: the monitoring of
drug safety rests squarely on the shoulders of clinical
research. Clinical trials must be science-based with
proper statistical methodologies and have clinically rel-
evant end points. Clinical research interacts directly
with the FDA and is responsible for the generation of
study reports with input from biostatisticians and reg-
ulatory affairs. Clinical research can also generate the
publications necessary for the marketing of any drug
product.
Regulatory affairs
The regulatory affairs department is the interface with
the FDA.It is their responsibility to ensure compliance
with the rules and regulations established by the Federal
Food Drug and Cosmetic Act (FDCA)
1 and its amend-
ments.
Marketing
The marketing group has the ultimate responsibility
for marketing and selling the drug. As a result, they
need product labeling that differentiates their drug
from those already marketed. Marketing has to pro-
vide creative concepts for the prescribing physician,
the patient, and the company’s senior management.
They also have to make sure that budget goals are met.
It is not uncommon for the marketing group to have
differences of opinion from both the clinical and regu-
latory groups within their own company,as well as with
the FDA.
Legal
In order for a drug to be financially successful, patent
protection is a key element.The legal group must submit
patents at the appropriate time and do all in its power to
avoid lawsuits from potential competitors. The legal
group also ensures that neither the FDA nor the Federal
Trade Commission (FTC) will challenge advertising and
promotional materials.
Food and Drug Administration
The FDA’s primary mission is to protect public health by
regulating the food supply,drugs,devices,and cosmetics.
The FDA regulates through the FDCA,Title 21 of the
Code of Federal Regulations (CFR),
2 and publications
in the Federal Register,
3 and by issuing guidance and
other regulatory documents.
Development philosophy
Don’t waste time: time is money
Time is a key factor in drug development. With finite
patent lives, the quicker a drug gets to the market, the
longer the revenue stream will be free of generic com-
petition. Therefore, in order to minimize the develop-
ment time,the team should:
• Plan carefully.
• Execute meticulously.
• Replan when necessary.
• Do only what is needed.
• Hire people who want to get the job done.
• Have pride in their product.
Basic research
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Selected abbreviations and acronyms
CBER Center for Biologics Evaluation and Research
CDER  Center for Drug Evaluation and Research 
CDRH Center for Devices and Radiological Health
CFR Code of Federal Regulations 
CFSAN Center for Food Safety and Applied Nutrition
CRO contract research organization
FDCA Federal Food,Drug,and Cosmetic Act
FTC Federal Trade Commission
IND investigational new drug
NDA new drug application215
Working with the FDA
Structure of the FDA
There are four FDA centers that have the potential to
interact in drug development.These are the Center for
Drug Evaluation and Research (CDER), Center for
Biologics Evaluation and Research (CBER),Center for
Devices and Radiological Health (CDRH),and Center
for Food Safety and Applied Nutrition (CFSAN).With
the advent of drug-delivery devices and dietary supple-
ments that can sometimes appear to be drugs, the
boundaries between the centers can at times be unclear.
As a result, it is always a good idea to know which cen-
ter will review a particular product.
Sources of information
There are several sources from which information can
be obtained about the FDA.Through the Freedom of
Information Act,
4 the United States government has
established a mechanism to obtain information direct-
ly from the FDA, which is otherwise not easily accessi-
ble through publicly available information.The FDA
can be contacted via letter or fax.The FDA also has
research services and can provide, on a fee-for-service
basis,specific information located within their archives.
Commercial companies also provide information ser-
vices.With the creation of the Internet,public informa-
tion is more readily available than ever before. The
FDA has a web site for each of its divisions with a
sophisticated search engine and document services
(http://www.fda.gov/).
How are regulatory requirements determined?
Sometimes it is obvious where a product will be
reviewed. A small molecule that will be used to treat
depression or schizophrenia will be reviewed in the Divi-
sion of Neurological Drug Products.If the designation is
not clear, in order to determine which center and which
group within that center will have primary product
review,it may be appropriate to ask the FDA for clarifi-
cation. Another alternative is to submit a Request for
Designation.
5 In the Request for Designation, the spon-
soring company may suggest what the primary reviewing
center should be. Since an original investigational new
drug (IND) is submitted to the Document Control Room
at FDA, the FDA will designate the primary reviewing
center and division if the sponsor does nothing.The latter
strategy is rarely adopted:it is almost always a good idea
to meet with FDA prior to an IND submission.
Contacting the FDA
What should be the initial exposure to FDA 
rules and regulations?
It is a good idea to be very familiar with the regulations.
The formal source of regulations is Title 21 of the CFR.
FDA guidance documents for specific issues are also
available. Consultants, including regulatory attorneys,
are available for consultations.Companies such as con-
tract research organizations (CROs) may also have reg-
ulatory specialists as part of their services.
How are specific toxicological, chemical,
and clinical requirements determined?
There are publications available in the Federal Register
as well as online at the FDA web site.It is a good idea to
review these publications,and then have access to experts
who are knowledgeable with specific requirements. It is
important to distinguish those vendors who provide ser-
vices such as toxicology and manufacturing from those
who plan toxicology and manufacturing programs. Just
because a site can perform services, does not mean that
they know how to design a development program.
What should be the initial contact with 
the FDA and how should it be carried out?
After completing the above background tasks,make an
initial call to the division of interest and briefly introduce
yourself. Discuss the project and its status and discuss
the option of an initial meeting. If a meeting is decided
upon,establish action items,plan meeting dates,send in
the briefing document with an agenda, and prepare for
the meeting.Find out how many copies the FDA needs.
Put in proposed meeting dates and blackout dates, let
the FDA know when the briefing document has been
sent,and confirm receipt over the phone.
Preparation for the initial FDA meeting
In general,it is usually a good idea to assign one person
to organize and champion the meeting. It is critical to
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meeting agenda; attendees; rationale for the product;
chemical characteristics of the drug and how it is made;
nonclinical pharmacology results; toxicology develop-
ment plan; clinical data, if available; clinical protocol
outline; reprints; and any specific questions to be
addressed.The document should be fully paginated,and
reproduced accurately so everything is legible, with a
clear table of contents.
How should an FDA meeting be conducted?
The most important aspects of an FDA meeting are to be
prepared and to get the FDA to share their position as to
how your drug should be developed. Remember, the
FDA has already seen your presentation, so there is no
need to spend a lot of time telling them what they already
know.We have participated in many FDA meetings with
no presentations. Bring to the meeting one experienced
scientist and one experienced clinician expert as partici-
pants.A clinical expert in the indication under study is a
major plus.If at all possible,the expert should have prior
FDA experience.If not,the expert must be coached as to
the goal of the meeting, and how to act and respond to
questions.Sometimes it is recommended to bring admin-
istrative and marketing executives so they can better
appreciate the regulatory process.Make sure each person
knows his/her role.If a presentation is decided upon,limit
the presentation to 10 to 15 minutes.During the meeting,
if possible, have two people take copious notes for the
generation of meeting minutes.Make sure that all of your
issues are addressed at the meeting and, if possible, chat
informally with the FDA after the meeting.
Conclusion
Bring the FDA in as part of the development team and
share ideas, set milestones, share data, maintain a dia-
logue,and keep no secrets.Remember:the FDA is part
of the team whether you like it or not. ❏
Basic research
Relaciones con la FDA durante el desarrollo 
de nuevos fármacos
Para que los programas de desarrollo de nuevos
fármacos resulten exitosos es imprescindible un tra-
bajo estrecho y de colaboración con las autorida-
des regulatorias. En los EEUU el equipo de desa-
rrollo de fármacos está integrado por miembros de
las disciplinas claves en el descubrimiento de una
nueva molécula (como investigadores clínicos,
especialistas en aspectos regulatorios, legales y de
marketing, químicos y toxicólogos) como también
por representantes de la Food and Drug Adminis-
tration (FDA). Los nuevos sistemas de regulación
promueven reuniones en distintas etapas del pro-
ceso; previo a la investigación propiamente tal (pre
INV), al final de la fase II, y antes de las propuestas
preliminares para la aplicación de la nueva molé-
cula (pre APL). También se fomentan las discusio-
nes informales vía fax o por teléfono cuando se
requiera. A través de una interacción proactiva con
la FDA la industria farmacéutica aumenta la pro-
babilidad de obtener buenos resultados durante el
programa de desarrollo de nuevos fármacos.
Les relations avec la FDA au cours 
du developpement d’un médicament 
Le succès des programmes de développement des
médicaments est essentiellement lié à une collabo-
ration étroite avec les autorités de tutelle. Aux
Etats-Unis, les équipes de développement regrou-
pent non seulement des membres des disciplines
clés de la découverte moléculaire, tels la recherche
clinique, le bureau de régulation, le marketing, la
chimie, la toxicologie et les affaires légales, mais
aussi des membres de la FDA (Food and Drug
Administration). Les nouveaux règlements sont
favorables à des réunions aux stades de nouveau
médicament réservé aux essais, de fin de phase II et
de pré-AMM (Autorisation de Mise sur le Marché)
d’une nouvelle molécule. Des contacts informels
par télécopie ou téléphone chaque fois que le
besoin s’en fait sentir sont également souhaitables.
En travaillant en liaison active avec la FDA, l’indus-
trie pharmaceutique augmente ses chances de suc-
cès dans le programme de développement molé-
culaire. 
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